Loading stock data…
BIOA
$16.79-0.06 (-0.36%)
Market ClosedLast close May 1
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioAge Labs, Inc. in the Healthcare sector is trading at $16.79. The stock is currently 30% below its 52-week high of $24.00, remaining 41.2% above its 200-day moving average. Technical signals show neutral RSI of 54 and bearish MACD signal, explaining why BIOA maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 54) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$16.79
Potential Upside
5%
Whystock Fair Value$17.63
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$53.33+217.6%
Range$23.00 – $73.00
Fundamentals
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$815.14M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.05%
Volume
Today's trading volume
324,984
Recent News
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile
BioAge Labs (NASDAQ:BIOA) executives outlined phase I results for its oral, brain-penetrant NLRP3 inhibitor BGE-102, highlighting what the company characterized as deep reductions in inflammatory biomarkers—particularly high-sensitivity C-reactive protein (hs-CRP)—alongside a tolerability profile ma
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?
Here is how Amarin (AMRN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
The mean of analysts' price targets for BioAge Labs, Inc. (BIOA) points to an 183.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioAge says early data suggest ‘best-in-class’ potential for inflammation drug
The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an inflammasome linked to a variety of health conditions.
BioAge Labs Highlights BGE-102 Catalysts, DME Study Plans and $285M Cash at Needham Conference
BioAge Labs (NASDAQ:BIOA) used a presentation at the 25th Annual Needham Virtual Healthcare Conference to outline near-term clinical catalysts for its lead NLRP3 inflammasome inhibitor and provide updates on additional pipeline programs and its cash position. Chief Financial Officer Dov Goldstein a